MARKET

ONCY

ONCY

Oncolytics Biotech Inc
NASDAQ
0.9151
-0.0149
-1.60%
After Hours: 0.9455 +0.0304 +3.32% 19:40 08/07 EDT
OPEN
0.9300
PREV CLOSE
0.9300
HIGH
0.9893
LOW
0.8801
VOLUME
548.68K
TURNOVER
--
52 WEEK HIGH
1.530
52 WEEK LOW
0.3258
MARKET CAP
88.40M
P/E (TTM)
-3.2776
1D
5D
1M
3M
1Y
5Y
1D
What to Expect from Oncolytics Biotech's Earnings
Benzinga · 19h ago
Oncolytics Biotech Inc <ONC.TO> expected to post a loss of 11 cents a share - Earnings Preview
Reuters · 1d ago
Oncolytics Biotech to Hold Virtual Annual Meeting and Announce Q2 Financial Results
TipRanks · 2d ago
Weekly Report: what happened at ONCY last week (0728-0801)?
Weekly Report · 4d ago
Buy Rating on Oncolytics Biotech: Strategic Focus on Pancreatic Cancer and Undervalued Stock Potential
TipRanks · 07/31 15:25
Oncolytics Biotech Engages FDA for Pivotal Pancreatic Cancer Study
TipRanks · 07/29 13:02
Oncolytics engaging FDA for registration-enabled pancreatic cancer trial
TipRanks · 07/29 12:35
Oncolytics Biotech Initiated Regulatory Discussions With FDA For Potential Registration-Enabled Study In First-Line Pancreatic Cancer
Benzinga · 07/29 12:32
More
About ONCY
Oncolytics Biotech Inc. is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. It acts by inducing anti-cancer immune responses and promotes an inflamed tumor phenotype, turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. The Company is also advancing its programs in hormone receptor-positive / human epidermal growth factor 2-negative (HR+/ HER2-) advanced and metastatic breast cancer (mBC) and metastatic pancreatic ductal adenocarcinoma (PDAC) to registration-enabled clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

Webull offers Oncolytics Biotech Inc (USA) stock information, including NASDAQ: ONCY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ONCY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ONCY stock methods without spending real money on the virtual paper trading platform.